Example: Heart Attack

Search clinical trials for: Cisplatin/ Etoposide

Total 493 results

NCT05873790

Not yet recruiting

Minimal Residual Disease Dynamic Monitoring in First-Line Serplulimab Plus Chemotherapy in Treatment of Extensive Small Cell Lung Cancer: An Observational Study

Lung Cancer
NCT05796089

Recruiting

TROG 20.01 CHEST RT: Chemotherapy and Immunotherapy in Extensive Stage Small Cell Lung Cancer With Thoracic Radiotherapy

Extensive-stage Small-cell Lung Cancer
NCT05765825

Not yet recruiting

Study of Low-Dose Radiotherapy Concurrent Cisplatin/Carboplatin Plus Etoposide With Serplulimab for Patients With ES-SCLC

Extensive-stage Small-cell Lung Cancer
NCT05745350

Not yet recruiting

First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC

Small Cell Lung Cancer Extensive Stage
NCT05705687

Recruiting

Validation of a Treatment Algorithm for Poor-Risk NSGCTnon Seminomatous Germ-cell Tumors (VAPOR)

Non-Seminomatous Germ Cell Tumor
NCT05694416

Not yet recruiting

Etoposide Plus Cisplatin Compared With Temozolomide in Patients With Glioblastoma

MGMT-Unmethylated Glioblastoma
NCT05668767

Not yet recruiting

Surufatinib in Combination of Durvalumab and EP/EC in the Firstly-line Treatment of ES-SCLC

Extensive-stage Small-cell Lung Cancer
NCT05664971

Recruiting

JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer

Advanced Lung Cancer
NCT05624996

Not yet recruiting

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer

Stage III Lung Cancer AJCC v8 Stage IIB Lung Cancer AJCC v8 Locally Advanced Lung Non-Small Cell Carcinoma
NCT05623319

Recruiting

Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC) (THOR)

SCLC,Extensive Stage
NCT05594290

Recruiting

Chemo-immunotherapy in Patients With Resectable Merkel Cell Carcinoma Prior to Surgery (MERCURY)

Merkel Cell Carcinoma
NCT05535166

Recruiting

Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma

Medulloblastoma
NCT05529251

Recruiting

De-escalation Study for Stage IIa/IIb < 3 cm Seminoma (EDEN)

Seminoma Stage II
NCT05496166

Not yet recruiting

The Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Cancer

Limited Stage Small Cell Lung Cancer
NCT05484583

Not yet recruiting

Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell Lung Cancer With Oligometastases

Lung Cancer Radiotherapy Extensive-stage Small-cell Lung Cancer
NCT05470595

Recruiting

A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung (LCNEC-ALPINE)

Large Cell Neuroendocrine Carcinoma of the Lung
NCT05443646

Not yet recruiting

A Phase II Study of Consolidation HLX10 (Serplulimab) Following Hypofractionated Radiotherapy With Concurrent Chemotherapy for Patients With Limited Stage Small Cell Lung Cancer（ASTRUM-LC01）

Limited Stage Small Cell Lung Cancer
NCT05403723

Recruiting

Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC

Extensive-stage Small-cell Lung Cancer
NCT05384015

Recruiting

Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer (PEERS)

Small Cell Lung Cancer Extensive Stage
NCT05353257

Recruiting

A Study to Evaluate the Efficacy and Safety of HLX10 in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

Limited-Stage Small Cell Lung Cancer
NCT05298423

Recruiting

Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006/KEYVIBE-006)

Carcinoma, Non-Small-Cell Lung
NCT05262985

Recruiting

Durvalumab (MEDI4736) Plus Platinum-based Chemotherapy in Advanced LCNEC: a Pilot Phase II Study

Patients With Advanced Treatment Naive LCNEC
NCT05245994

Recruiting

An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese

Small Cell Lung Cancer Lung Cancer Durvalumab
NCT05244642

Recruiting

A Phase III Study to Evaluate the Efficacy and Safety of Penpulimab in the Relapsed and Refractory Classical Hodgkin's Lymphoma

Hodgkin Disease Lymphoma
NCT05224141

Recruiting

Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008, KEYVIBE-008)

Small Cell Lung Carcinoma
NCT05161533

Recruiting

Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial

Stage IVA Lung Cancer AJCC v8 Stage IVB Lung Cancer AJCC v8 Stage IV Lung Cancer AJCC v8 Extensive Stage Lung Small Cell Carcinoma
NCT05142865

Not yet recruiting

Camrelizumab Combined With Chemotherapy and Apatinib for Extrapulmonary Neuroendocrine Carcinomas

Advanced or Metastatic EP-NEC
NCT05139095

Recruiting

Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia

Gestational Trophoblastic Neoplasia
NCT05128630

Recruiting

Chemo-immunotherapy, Hypo-fractionated RT and Maintenance Immunotherapy for Stage III NSCLC. (DEDALUS)

NSCLC, Stage III
NCT05124951

Recruiting

The Efficacy of WVI in Patients With Localized Basal Ganglia Intracranial Germ Cell Tumors

Intracranial Germ Cell CNS Tumor, Childhood
NCT05092412

Recruiting

Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC

Lung Cancer Extensive-stage Small-cell Lung Cancer Durvalumab
NCT05076786

Recruiting

Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine Carcinoma

Neuroendocrine Tumors Neuroendocrine Carcinoma
NCT05058651

Recruiting

Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

Advanced Extrapulmonary Neuroendocrine Carcinoma Metastatic Extrapulmonary Neuroendocrine Carcinoma Recurrent Extrapulmonary Neuroendocrine Carcinoma Unresectable Extrapulmonary Neuroendocrine Carcinoma
NCT05034133

Recruiting

Durvalumab With Chemotherapy Followed by Sequential Radiotherapy for Limited Stage Small Cell Lung Cancer

Limited Stage Small Cell Lung Cancer
NCT05019716

Recruiting

Testing the Safety and Efficacy of the Addition of A New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Etoposide and Cisplatin) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma

Metastatic NUT Carcinoma Unresectable NUT Carcinoma Advanced NUT Carcinoma

Search clinical trials for: Cisplatin/ Etoposide

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malta

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations